Axovant Sciences Ltd. | Ownership
Companies that own Axovant Sciences Ltd.
Renaissance Technologies LLC
1,303,600
1.07%
-630,200
0%
06/30/2018
BlackRock Fund Advisors
1,252,858
1.03%
-1,494,922
0%
06/30/2018
Ziff Brothers Investments LLC
1,207,958
0.99%
0
1.25%
12/31/2017
PRIMECAP Management Co.
1,082,900
0.89%
-101,400
0%
06/30/2018
Adage Capital Management LP
1,000,000
0.82%
1,000,000
0.01%
06/30/2018
Millennium Management LLC
961,987
0.79%
-368,923
0%
06/30/2018
Hudson Bay Capital Management LP
771,900
0.63%
196,900
0.06%
06/30/2018
Connor, Clark & Lunn Investment Management Ltd.
495,450
0.41%
320,450
0.01%
06/30/2018
Marshall Wace North America LP
464,653
0.38%
464,653
0.01%
06/30/2018
Two Sigma Investments LP
358,515
0.28%
-211,143
0%
06/30/2018
| Address |
11-12 St. James's Square
London London & South East SWIY 4LB
United Kingdom
|
|
Employees
|
- |
| Website |
http://www.axovant.com |
| Updated |
09/14/2018 |
| Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics in the fields of neurology and psychiatry. Its therapeutic focus are Parkinson's Disease and Lewy Body Dementia. It operates through the following geographical sgements: United States, Switzerland, Bermuda, and Other. |
